(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Iran's stolen futures: The arrested Iranians at risk of execution by the regime - 2Posts falsely claim Netanyahu video fabricated to cover up his death
- 310 Hints for an Effective New employee screening
- 4More parents refusing vitamin K shots for newborns, study finds
- 5Go With The Breeze: Grand Paragliding Spots On the planet
- Most loved Caf\u00e9 Chain: Where Do You Get Your Caffeine Fix
- Limited Rain Chances in Brazil Boost Coffee Prices
- Rick Steves' Newest Guidebook Is A Fresh Perspective On Italy Spilling The Country's Secrets
- Figure out how to Perceive Warnings while Looking for an Auto Collision Lawyer
- The most effective method to Stay away from Normal Traps While Recruiting a Material Organization
- Germany paves the way for tighter EU asylum rules
- Vote in favor of your Number one Kind of Gems
- Why More Couples Are Choosing Africa For Their Honeymoon
- Top 20 Compelling Business Books for Progress
